The aim was to determine long-term overall, breast cancer-specific and metastasis-free survival as well as axillary relapse rate from a pooled analysis of two randomized trials in women with operable breast cancer. These trials compared axillary node sampling (ANS), combined with axillary radiotherapy (AXRT) if the sampled nodes were involved, with axillary node clearance (ANC).
Introduction
Management of the axilla in invasive breast cancer remains an area of ongoing controversy and debate. For many years it was practice for patients with invasive cancer to have an axillary lymph node clearance (ANC) regardless of whether nodes were thought to be involved before surgery 1, 2 .
ANC carries considerable morbidity in terms of lymphoedema, pain, damage to the intercostobrachial nerve, and interference with shoulder movement 3 -5 . Axillary node sampling (ANS) is a technique pioneered in the Edinburgh Breast Unit in the early 1980s. The aim was to offer a minimally invasive operative approach to assess the status of the axillary nodes and avoid ANC in patients without histological evidence of axillary node involvement. It was a technique that others did not find easy to learn and was therefore not widely used outside of a few major breast units. The ANS technique was developed and validated through a series of randomized trials and was shown to provide a minimally invasive, accurate method of assessing axillary node status 6 -8 . ANS was superseded first by blue dye-directed sampling of the axillary node and then by sentinel lymph node biopsy (SLNB) using both radioisotope and blue dye 9, 10 . The ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance) trial 5 showed less arm morbidity and better quality of life after SLNB compared with ANC, with similar morbidity for both ANS and SLNB. The reduction in morbidity is the major reason why SLNB is now used widely in patients with clinically node-negative disease.
The move to fewer axillary clearance operations has been shown to be safe, at least in the first decade after treatment, with equivalent survival and local recurrence rates for SLNB compared with ANC among women without axillary node involvement. Even in node-positive patients the routine use of ANC is now being questioned. In patients with one or two involved nodes on SLNB, having breast-conserving surgery and whole-breast radiotherapy, the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial 11 showed no improvement in axillary recurrence rates or overall survival for ANC compared with SLNB alone. Recently the AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery) trial has shown that axillary radiotherapy (AXRT) gives short-term outcomes equal to those of ANC in patients with involved nodes on SLNB. Although the National Institute for Health and Care Excellence (NICE) 12 still recommends ANC for patients with axillary lymph node-positive breast cancer, American Society of Clinical Oncology (ASCO) guidelines 13 state that patients with one or two positive nodes undergoing breast-conserving surgery and whole-breast radiotherapy, who fulfil Z0011 entry criteria, do not require routine ANC.
Over 30 years ago the Edinburgh Breast Unit initiated two randomized clinical trials (RCTs) 6,7 comparing ANC with ANS followed by AXRT if the sampled nodes were involved. Updated results from these two cohorts are presented here, providing the first long-term data comparing ANS with or without AXRT versus ANC. Results are presented for overall survival, breast cancer-specific survival, metastasis-free survival and axillary recurrence patterns among women with a follow-up of more than 20 years since treatment.
Methods
Two consecutive RCTs 6,7 on ANS versus ANC were used in the pooled analysis. The first trial 7 enrolled patients having mastectomy and the second 6 included patients treated by breast-conserving surgery. Approval was sought for both trials from a local ethics committee, and informed consent was given by all patients.
The inclusion criteria for the two trials were: operable invasive breast cancer (T1-T3, N0-N1, M0), and patient suitable for both surgery and radiotherapy. The exclusion criteria were: inoperable or clinically multicentric tumour, ductal carcinoma in situ, fixed axillary nodes, previous invasive carcinoma (except skin basal cell carcinoma), Paget's disease of the nipple and male sex. Patients aged over 70 years were also excluded from the breast conservation trial 6 . All patients underwent investigation to exclude metastatic disease, including liver ultrasonography, skeletal scintigraphy, radiography of the chest, abdomen and pelvis, and haematological and liver function testing. The study endpoints were: overall survival, breast cancer-specific survival, time to locoregional relapse and time to distant metastasis.
Axillary surgery
In ANS the surgeon identified four palpable axillary lymph nodes. These nodes were taken primarily from level I in the lower axilla; the number of nodes excised ranged from two to eight. Patients randomized to ANC had all nodes removed up to and including level III. Node involvement was determined histologically following ANS or ANC.
Axillary radiotherapy
Patients with node-positive disease found after ANS were treated with AXRT. AXRT was given to all node-positive patients who had ANS, apart from five who were randomized to the no-radiotherapy arm of the Scottish Conservation Trial; these patients were omitted from the present analysis. Patients who underwent ANC and who had involved nodes did not receive radiotherapy.
In the breast conservation trial, regional lymphatics were treated by a direct anterior field covering the axilla and supraclavicular fossa with a posterior axillary boost, bringing the mid-axillary dose to 4500 Gy in 20 fractions over 4 weeks 6 .
In the mastectomy trial, radiotherapy included the ipsilateral internal mammary chain, shoulder fields and supraclavicular fossa 7 . During the course of the trial modifications were made to the radiotherapy treatment, the total dose being reduced from 4500 Gy in 20 fractions to 4000 Gy in ten fractions over 4 weeks.
Systemic therapy
All patients received standard postoperative adjuvant chemotherapy or endocrine treatment for the time interval of the study. Chemotherapy mainly comprised a cyclophosphamide, methotrexate and fluorouracil regimen or Adriamycin (doxorubicin)-based regimens. Treatments were based on the results of pathology, including axillary lymph node histology and hormone receptor status. Some oestrogen receptor (ER)-negative patients did not have chemotherapy, and many ER-negative patients received tamoxifen because of the belief at the time that these patients might also benefit from such treatment. In addition, not all women with ER-positive cancers received tamoxifen. Some premenopausal women with ER-positive cancers had an oophorectomy.
Follow-up
Patients were followed up in outpatient clinics in the oncology and breast surgery departments, every 3 months for 2 years, 6 monthly from years 2 to 5 and annually thereafter. Patients who were disease-free at 10 years were discharged to primary care. Follow-up for these patients was by yearly contact with the general practitioner.
Data available from the pooled trials
Demographic and clinical information available included: age, type of breast cancer, TNM stage, tumour size on pathology and lymph node status (number of nodes excised, number of positive nodes), type of axillary operation, radiotherapy to the axilla, radiotherapy to the breast, ER status, and adjuvant systemic therapy.
Data were updated from previous publications using existing departmental databases, electronic patient records and case notes. Cause of death was established from death certificates archived at Register House, Edinburgh. Breast cancer was considered to be the cause of death only if listed within part 1 of the death certificate.
Statistical analysis
Kaplan-Meier survival curves were used to show survival and relapse rates. Cox survival models were used to generate hazard ratios (HRs) and 95 per cent c.i. The proportional hazards assumption was tested and found to hold in all analyses. The log rank test was used to test for equality of survival distributions and to assess any statistically significant differences between randomized groups. All tests were two-sided. A limited number of subgroup analyses were performed to generate hypotheses. Data analysis was carried out by an independent statistician using SPSS ® for Windows ® version 19.0 (IBM, Armonk, New York, USA).
Results
In total, 855 women with invasive breast cancer were randomized to either ANC (424) or ANS ± AXRT (431) in the two trials between 1980 and 1995 ( Fig. 1) . Follow-up to death or at least 20 years was available for 799 patients; only 56 patients (6⋅5 per cent) were lost to follow-up, mostly owing to change of address. The median and mean follow-up times were 19⋅4 and 19⋅9 years respectively.
Node-positive disease
Information was available for 301 women with node-positive disease (37⋅7 per cent of all patients). This excludes patients randomized to the no-radiotherapy arm of the Scottish Conservation Trial and patients for whom the number of nodes was not recorded. This node-positive group was subdivided according to number of positive lymph nodes ( Table 1) .
Overall survival
The overall median survival time in these patients was estimated at 13⋅8 years (ANC 13⋅2 years, ANS + AXRT 14⋅4 years). There was no difference in overall survival between ANC and ANS + AXRT (P = 0⋅876, log rank test). There was no evidence to suggest that ANS + AXRT gave a survival advantage or disadvantage over ANC in patients with node-positive disease (HR 0⋅98, 95 per cent c.i. 0⋅75 to 1⋅28; P = 0⋅876). There was no difference in survival between patients with one versus two to four involved nodes (P = 0⋅159). However, patients with five to nine (HR 1⋅73, 1⋅11 to 2⋅71; P = 0⋅016) and ten or more (HR 2⋅45, 1⋅51 to 3⋅98; P < 0⋅001) involved nodes had significantly higher risks of death than patients with only one node involved.
Age over 65 years (HR 2⋅18, 1⋅51 to 3⋅15; P < 0⋅001) and at least ten involved axillary nodes (HR 2⋅45, 1⋅51 to 3⋅98; P < 0⋅001) were the only significant predictors of overall survival. Axillary surgery was not found to be a significant predictor of death once other factors had been accounted for in patients with node-positive tumours (P = 0⋅254).
Breast cancer-specific survival
In patients with axillary lymph node-positive disease, 137 (62⋅0 per cent) of the 221 deaths were from breast cancer. 
Axillary node clearance n = 424 Fig. 1 Initial randomization of patients to axillary node sampling or axillary node clearance There was no evidence to suggest that ANS + AXRT gave a survival advantage or disadvantage over ANC in terms of death from breast cancer (HR 1⋅07, 95 per cent c.i. 0⋅77 to 1⋅50; P = 0⋅688).
Axillary relapse
In women with node-positive disease, a difference in time to axillary recurrence between ANC and ANS + AXRT was shown (P = 0⋅041, Mantel-Cox test) (Fig. 2) . Patients who had ANS + AXRT were more than twice as likely as those having ANC to develop an axillary recurrence (HR 2⋅64, 95 per cent c.i. 1⋅00 to 6⋅95; P = 0⋅049). Numbers of axillary recurrences, by type of axillary surgery and node status, are detailed in Table 2 . There were no survivors among patients who had an axillary relapse after ANC at a median follow-up of 19⋅4 years.
Time to metastases
There was no evidence to suggest that ANS + AXRT had a metastasis-free survival advantage or disadvantage over ANC (HR 1⋅03, 95 per cent c.i. 0⋅75 to 1⋅43; P = 0⋅847). As expected, patients with a greater number of positive nodes had a significantly higher risk of metastasis. For patients with between five and nine involved nodes the HR for an axillary relapse was 2⋅24 (95 per cent c.i. 1⋅33 to 3⋅76; P = 0⋅002) compared with those with fewer involved nodes. For those with at least ten involved nodes the HR was 3⋅45 (1⋅99 to 5⋅97; P < 0⋅001) versus patients with fewer than ten involved nodes. There was no evidence to suggest that axillary surgery had any impact on time to metastasis once node status had been taken into account in either univariable (P = 0⋅847) or multivariable (P = 0⋅090) analysis.
Node-negative disease
A total of 498 women (62⋅3 per cent) had node-negative disease. None of these patients had AXRT. The overall median survival time for this group was estimated at 22⋅1 years, 22⋅1 years for those who underwent ANC and 22⋅0 years for women who had ANS. Values in parentheses are percentages.
Overall survival
In patients with lymph node-negative disease there was no significant difference in overall survival for those treated by ANC versus ANS (P = 0⋅748). Age over 65 years (HR 2⋅63, 95 per cent c.i. 1⋅98 to 3⋅52; P < 0⋅001) and type of surgery (mastectomy versus breast conservation) (HR 1⋅34, 1⋅05 to 1⋅74; P = 0⋅021) were significant predictors of overall survival in multivariable analysis. Axillary surgery was not a significant predictor of death once other factors had been accounted for (P = 0⋅791).
Breast cancer-specific survival
There was no significant difference in death from breast cancer after ANS versus ANC in patients with node-negative disease (HR 0⋅88, 95 per cent c.i. 0⋅58 to 1⋅34; P = 0⋅557). Death from breast cancer was significantly less likely in patients with negative axillary nodes than in women with axillary node-positive disease (P < 0⋅001), with no evidence of any effect of axillary treatment type (Fig. 3) .
Axillary relapse
There were no new local recurrences after the first decade in patients with node-negative disease. All axillary recurrences in the ANC category occurred within the first 4 years, and those in the ANS group within 9 years. There was a significant difference in time to axillary recurrence between the ANC and ANS groups (P = 0⋅009). The risk of axillary relapse was significantly higher after ANS than ANC (3⋅53, 95 per cent c.i. 1⋅29 to 9⋅63; P = 0⋅014). In the Cox regression model, which included type of breast surgery and tumour size, there was no evidence that any variable other than axillary surgery affected the time to axillary recurrence.
In the whole cohort, the annual risk of axillary recurrence increased from year to year. This was not, however, statistically significant (P = 0⋅633). Neither was relapse linear over time ( Table 3) . Between 1983 and 1987, no patients had surgery owing to the timing of the two trials 6, 7 . Values in parentheses are 95 per cent c.i.
Time to metastasis
There was no evidence to suggest that the metastasis-free survival time differed between ANS and ANC groups in patients with node-negative disease (HR 1⋅03, 95 per cent c.i. 0⋅70 to 1⋅51; P = 0⋅877).
Discussion
The present pooled analysis from two RCTs provides long-term follow-up data for 799 patients randomized to two different methods of axillary treatment. Median follow-up was 19⋅4 years, with follow-up to death or at least 20 years for over 90 per cent of the cohort. This study showed no significant differences between ANC and ANS, combined with AXRT if the sampled nodes were involved, in terms of overall, breast cancer-specific and metastasis-free survival in patients with operable invasive breast cancer (T1-T3, N0-N1, M0). The lack of difference in breast cancer-specific outcomes adds to the data on metastasis-free survival, and confirms that the type of axillary treatment does not affect survival.
Most axillary recurrences (39 of 40) occurred in the first 10 years after commencing treatment, with the final local recurrence occurring in the 18th year. This is of importance for studies whose primary endpoint is locoregional events, such as the ALMANAC trial 5 and the new POS-NOC (POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy) UK SLNB study. Follow-up in excess of 5 years is required if the primary endpoint is axillary recurrence, as in the POSNOC study. The AMAROS trial by Rutgers and colleagues compared SLNB + AXRT with ANC in women with a positive SLNB, and showed no difference in overall disease-free survival at 5 years between the two groups. In the present study, the axillary recurrence rate was higher with ANS (with AXRT if sampled nodes were involved) than ANC in both node-negative and node-positive patients. However, this increased rate of axillary relapse did not have an adverse effect on survival.
There are a number of reasons for this. First, ANS is not easy to learn, and there is the potential for sampling error. The operations in the RCTs were performed by a range of consultant and trainee surgeons, which might have increased the risk of positive nodes being missed. However, in a paper by Steele and co-workers 14 , 417 patients were allocated randomly to ANS or ANC. At the completion of the procedure, 135 patients who had undergone ANS were randomized to ANC or no further surgery. No patient had positive nodes on ANC that were negative on ANS, confirming the accuracy of the sampling technique when performed correctly. Apart from the latter study, there are limited data on the false-negative rate of ANS. In contrast, there is huge amount of data on the false-negative rate of SLNB, with a meta-analysis 15 reporting a rate of 7⋅3 per cent; the rate for ANS is likely to be higher.
Second, in the present study the number of nodes sampled ranged from two to eight. Many of the axillary recurrences in patients with negative ANS could have been due to involved nodes being missed by the surgeon. In studies of ANS and SLNB, the more nodes that are removed and examined, the lower the false-negative rate. Additionally, the number of nodes involved helps guide decisions regarding adjuvant systemic treatment, which would have influenced the use of adjuvant systemic therapy in the RCTs analysed here 6, 7 . Patients having ANS had fewer nodes sampled, which may have resulted in less adjuvant therapy being given. This difference was small in reality, but the lack of adjuvant therapy in women with a false-negative ANS could have influenced the rate of axillary recurrence.
There were no long-term survivors among patients who had an axillary relapse after ANC. This demonstrates that an axillary recurrence is salvageable with further axillary surgery with or without AXRT after ANS or SLNB, but relapse after ANC is biologically quite different. Patients with clinically involved nodes (N1) were eligible to enter the RCTs 6,7 , so some recurrences in the ANS groups will have represented residual axillary disease not controlled by AXRT. ANC was an option for such women, many of whom did well after this procedure.
The rates of axillary recurrence were higher in this series than in the Z0011 11 and AMAROS trials. These differences are likely to be explained by the more advanced stage of disease in the present trials and the systemic therapy administered. Not all ER-positive patients in the present cohort received hormone therapy, and not all ER-negative patients had chemotherapy. There was a significantly lower rate of axillary recurrence among patients who did receive endocrine therapy, The effects of improved systemic therapy in terms of reducing local and regional recurrence have been well documented in other randomized trials 11, 16 .
In this study, node status had a great influence on long-term outcomes, whereas the type of nodal treatment did not. The greater the number of positive lymph nodes involved, the greater the risk of death. Only age and the number of nodes were significant predictors of time to death. This reinforces previous findings 11, 16 -18 that type of axillary treatment is not a predictor of survival. The importance of the present study lies in its demonstration that axillary treatment does not influence long-term survival, despite an increased rate of axillary recurrence with ANS (with or without AXRT). There is clearly no survival benefit to a more aggressive surgical approach to the axilla.
Axillary treatments are not without morbidity and, although this was not recorded routinely, detailed morbidity data for patients having breast-conserving surgery were reported previously 6 . In this group lymphoedema rates were significantly higher with ANC than ANS with or without AXRT, although AXRT significantly influenced shoulder morbidity and reduced the range of some shoulder movements. The AMAROS trial 13 has also confirmed the much higher rates of lymphoedema with ANC. In AMAROS there was, however, no effect of AXRT on shoulder movement. Since the trials included in the present study, radiotherapy techniques and planning have improved, and techniques to avoid shoulder capsule irradiation are now routine, which probably explains the difference in shoulder morbidity in the present study and AMAROS trial.
This study raises the question of whether women having whole-breast radiotherapy and are deemed to require axillary treatment should be offered AXRT rather than ANC because it produces similar long-term survival outcomes, but results in less significant morbidity and a much lower rate of lymphoedema. A selective approach to the axilla is supported by the present findings, which show that axillary treatment does not influence long-term survival.
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